title: Biologic Therapy in Psoriasis: Safety Profile.
abstract: This review focuses on the emerging concepts concerning the efficacy profile of biological drugs in psoriasis ranging from moderate to severe, and attempts to provide the most recent individual positioning of biologics in treating psoriasis. Biologic agents targeting towards specific immune mediators have emerged as treatment options for patients with moderate to-severe plaque psoriasis unresponsive or intolerant to traditional systemic agents. Data on the safety of biologics are available for up to 5 years in psoriasis and are on the whole reassuring. National registries are still evolving and will provide data on safety, to help the long-term monitoring of patients with psoriasis ongoing biological treatment. Although several biologics have demonstrated good efficacy and tolerability in short-term trials, treatment guidelines recommend them as third line therapies due to relative lack of long-term safety data, especially for those who have been commercialized recently. Here, we have reviewed the long-term safety data obtained from National Registries, randomized controlled trials, open-label extension studies and meta-analyses on etanercept, infliximab, adalimumab, and ustekinumab in the treatment of adults with moderate to severe plaque psoriasis.
authors.affiliation: Dermatology Unit Department of Clinical and Molecular Sciences, Polytechnic Marche University, Ancona, Italy. anna.campanati@gmail.com.
authors.forename: Anna
authors.initials: A
authors.lastname: Campanati
authors.forename: Giulia
authors.initials: G
authors.lastname: Ganzetti
authors.forename: K
authors.initials: K
authors.lastname: Giuliodori
authors.forename: Elisa
authors.initials: E
authors.lastname: Molinelli
authors.forename: A
authors.initials: A
authors.lastname: Offidani
mesh_terms: D000068879:Adalimumab / Q000627:therapeutic use; D000818:Animals; D001691:Biological Therapy / Q000009:adverse effects* / Q000379:methods*; D003879:Dermatologic Agents / Q000627:therapeutic use; D064420:Drug-Related Side Effects and Adverse Reactions / Q000175:diagnosis / Q000209:etiology / Q000276:immunology; D000068800:Etanercept / Q000627:therapeutic use; D006801:Humans; D000069285:Infliximab / Q000627:therapeutic use; D011565:Psoriasis / Q000175:diagnosis / Q000188:drug therapy* / Q000276:immunology; D016032:Randomized Controlled Trials as Topic / Q000379:methods; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors / Q000276:immunology
chemical_list: D003879:Dermatologic Agents; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab; D000068879:Adalimumab; D000068800:Etanercept